Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-PACE-Melphalan vs Melphalan in Active Multiple Myeloma
NCT00083915Phase 3Completed
- Sponsor
- University of Arkansas
- Start
- Jun 2001
- Primary completion
- Jun 2010
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Cisplatin micelle injection (HA132), cyclophosphamide, pegylated liposomal doxorubicin, etoposide, thalidomide and 1 more in multiple myeloma (MM) (2 arms), sponsored by University of Arkansas. Primary endpoints: Complete Remission / Near Complete Remission / Very Good Partial Remission Rate at 3 years, Event-Free Survival at 3 years and 1 more. Started Jun 2001; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)cyclophosphamidepegylated liposomal doxorubicinetoposidethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00083915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083915.